Skip to main content
Top
Published in: PharmacoEconomics 8/2016

01-08-2016 | Current Opinion

Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges

Authors: Sevan Dirmesropian, James G. Wood, C. Raina MacIntyre, Philippe Beutels, Anthony T. Newall

Published in: PharmacoEconomics | Issue 8/2016

Login to get access

Abstract

High-income countries are undergoing demographic transitions towards populations with substantial larger proportions of older adults. Due to the increased susceptibility of older adults to infectious diseases and their consequences, vaccination programmes are an important health intervention to help maintain healthy ageing. While much of the existing literature suggests that current vaccination programmes targeted at older adults and the elderly are likely to be cost effective in high-income countries, we argue that it is important to more fully consider some important issues and challenges. Since the majority of vaccines have been developed for children, economic evaluations of vaccination programmes have consequentially tended to focus on this age group and on how to incorporate herd-immunity effects. While programmes targeted at older adults and the elderly may also induce some herd effects, there are other important challenges to consider in these economic evaluations. For example, age and time effects in relation to vaccine efficacy and duration of immunity, as well as heterogeneity between targeted individuals in terms of risk of infection, severity of disease and response to vaccination. For some pathogens, there is also the potential for interactions with childhood programmes in the form of herd-immunity effects.
Appendix
Available only for authorised users
Literature
2.
go back to reference Anderson GF, Hussey PS. Population aging: a comparison among industrialized countries. Health Aff (Millwood). 2000;19(3):191–203.CrossRefPubMed Anderson GF, Hussey PS. Population aging: a comparison among industrialized countries. Health Aff (Millwood). 2000;19(3):191–203.CrossRefPubMed
3.
go back to reference Schoen C, et al. A survey of primary care physicians in eleven countries, 2009: perspectives on care, costs, and experiences. Health Aff (Project Hope). 2009;28(6):w1171–83.CrossRef Schoen C, et al. A survey of primary care physicians in eleven countries, 2009: perspectives on care, costs, and experiences. Health Aff (Project Hope). 2009;28(6):w1171–83.CrossRef
6.
go back to reference Herndler-Brandstetter D, Cioca DP, Grubeck-Loebenstein B. Immunizations in the elderly: do they live up to their promise? Wien Med Wochenschr. 2006;156(5–6):130–41.CrossRefPubMed Herndler-Brandstetter D, Cioca DP, Grubeck-Loebenstein B. Immunizations in the elderly: do they live up to their promise? Wien Med Wochenschr. 2006;156(5–6):130–41.CrossRefPubMed
7.
go back to reference Centres for Disease Control and Prevention. Active Bacterial Core Surveillance (ABC’s) report: emerging infection program network, Streptococcus pneumoniae surveillance report. Atlanta: Centres for Disease Control and Prevention; 2013. Centres for Disease Control and Prevention. Active Bacterial Core Surveillance (ABC’s) report: emerging infection program network, Streptococcus pneumoniae surveillance report. Atlanta: Centres for Disease Control and Prevention; 2013.
9.
go back to reference Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833.
10.
go back to reference Esposito S, et al. Vaccine-preventable diseases: from paediatric to adult targets. Eur J Intern Med. 2014;25(3):203–12.CrossRefPubMed Esposito S, et al. Vaccine-preventable diseases: from paediatric to adult targets. Eur J Intern Med. 2014;25(3):203–12.CrossRefPubMed
11.
go back to reference Kimman TG, et al. Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. Vaccine. 2006;24(22):4769–78.CrossRefPubMed Kimman TG, et al. Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. Vaccine. 2006;24(22):4769–78.CrossRefPubMed
14.
go back to reference National Health and Medical Research Council (NHMRC). The Australian Immunisation Handbook 10th Edition. Canberra: Australian Government Department of Health and Ageing; 2013. National Health and Medical Research Council (NHMRC). The Australian Immunisation Handbook 10th Edition. Canberra: Australian Government Department of Health and Ageing; 2013.
15.
go back to reference Newall AT, Jit M, Beutels P. Economic evaluations of childhood influenza vaccination: a critical review. Pharmacoeconomics. 2012;30(8):647–60.CrossRefPubMed Newall AT, Jit M, Beutels P. Economic evaluations of childhood influenza vaccination: a critical review. Pharmacoeconomics. 2012;30(8):647–60.CrossRefPubMed
16.
go back to reference Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making. 2003;23(1):76–82.CrossRefPubMed Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making. 2003;23(1):76–82.CrossRefPubMed
18.
go back to reference Ogilvie I, et al. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine. 2009;27(36):4891–904.CrossRefPubMed Ogilvie I, et al. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine. 2009;27(36):4891–904.CrossRefPubMed
19.
go back to reference Postma MJ, et al. Further evidence for favorable cost-effectiveness of elderly influenza vaccination. Expert Rev Pharmacoeconom Outcomes Res. 2006;6(2):215–27.CrossRef Postma MJ, et al. Further evidence for favorable cost-effectiveness of elderly influenza vaccination. Expert Rev Pharmacoeconom Outcomes Res. 2006;6(2):215–27.CrossRef
20.
go back to reference Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics. 2013;31(2):125–36.CrossRefPubMed Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics. 2013;31(2):125–36.CrossRefPubMed
21.
go back to reference Newall AT, et al. Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. Vaccine. 2014;32(7):759–65.CrossRefPubMed Newall AT, et al. Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. Vaccine. 2014;32(7):759–65.CrossRefPubMed
23.
go back to reference Grutters JPC, et al. Acknowledging patient heterogeneity in economic evaluation: a systematic literature review. Pharmacoeconomics. 2013;31(2):111–23.CrossRefPubMed Grutters JPC, et al. Acknowledging patient heterogeneity in economic evaluation: a systematic literature review. Pharmacoeconomics. 2013;31(2):111–23.CrossRefPubMed
25.
26.
go back to reference Lelic A, et al. The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age. PLoS Pathog. 2012;8(12):e1003076.CrossRefPubMedPubMedCentral Lelic A, et al. The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age. PLoS Pathog. 2012;8(12):e1003076.CrossRefPubMedPubMedCentral
27.
go back to reference Weinberger B, et al. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis. 2008;46(7):1078–84.CrossRefPubMed Weinberger B, et al. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis. 2008;46(7):1078–84.CrossRefPubMed
28.
go back to reference Shapiro ED, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453–60.CrossRefPubMed Shapiro ED, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453–60.CrossRefPubMed
29.
go back to reference Castilla J, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill. 2013;18(5) (pii:20388). Castilla J, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill. 2013;18(5) (pii:20388).
30.
go back to reference Oxman MN, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.CrossRefPubMed Oxman MN, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.CrossRefPubMed
31.
go back to reference Ultsch B, et al. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res. 2013;13(1):359.CrossRefPubMedPubMedCentral Ultsch B, et al. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res. 2013;13(1):359.CrossRefPubMedPubMedCentral
32.
go back to reference Pawelec G. Immunosenescence: impact in the young as well as the old? Mech Ageing Dev. 1999;108(1):1–7.CrossRefPubMed Pawelec G. Immunosenescence: impact in the young as well as the old? Mech Ageing Dev. 1999;108(1):1–7.CrossRefPubMed
35.
go back to reference Schmader KE, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320–8.CrossRefPubMedPubMedCentral Schmader KE, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320–8.CrossRefPubMedPubMedCentral
36.
go back to reference Nobili A, Garattini S, Mannucci PM. Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J Comorbid. 2011;1:28–44.CrossRef Nobili A, Garattini S, Mannucci PM. Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J Comorbid. 2011;1:28–44.CrossRef
37.
go back to reference Moberley S, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1(1):CD000422. Moberley S, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1(1):CD000422.
38.
go back to reference Marengoni A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430–9.CrossRefPubMed Marengoni A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430–9.CrossRefPubMed
39.
go back to reference Constans T, Alix E, Dardaine V. Protein-calorie malnutrition in the elderly: diagnostic methods and epidemiology [in French]. Presse Med. 2000;29(39):2171–6.PubMed Constans T, Alix E, Dardaine V. Protein-calorie malnutrition in the elderly: diagnostic methods and epidemiology [in French]. Presse Med. 2000;29(39):2171–6.PubMed
40.
42.
go back to reference Mitnitski A, et al. Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality. J Am Geriatr Soc. 2005;53(12):2184–9.CrossRefPubMed Mitnitski A, et al. Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality. J Am Geriatr Soc. 2005;53(12):2184–9.CrossRefPubMed
43.
go back to reference Rockwood K, et al. Long-term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70. J Am Geriatr Soc. 2006;54(6):975–9.CrossRefPubMed Rockwood K, et al. Long-term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70. J Am Geriatr Soc. 2006;54(6):975–9.CrossRefPubMed
44.
go back to reference Ridda I, et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine. 2009;27(10):1628–36.CrossRefPubMed Ridda I, et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine. 2009;27(10):1628–36.CrossRefPubMed
45.
go back to reference Yao X, et al. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine. 2011;29(31):5015–21.CrossRefPubMedPubMedCentral Yao X, et al. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine. 2011;29(31):5015–21.CrossRefPubMedPubMedCentral
46.
go back to reference MacIntyre CR. Elderly vaccination: the glass is half full. Sci Res. 2013;5(12A):80–5. MacIntyre CR. Elderly vaccination: the glass is half full. Sci Res. 2013;5(12A):80–5.
47.
go back to reference Ridda I, et al. Predictors of pneumococcal vaccination uptake in hospitalized patients aged 65 years and over shortly following the commencement of a publicly funded National Pneumococcal Vaccination Program in Australia. Hum Vaccin. 2007;3(3):83–6.CrossRefPubMed Ridda I, et al. Predictors of pneumococcal vaccination uptake in hospitalized patients aged 65 years and over shortly following the commencement of a publicly funded National Pneumococcal Vaccination Program in Australia. Hum Vaccin. 2007;3(3):83–6.CrossRefPubMed
48.
go back to reference Ultsch B, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics (Epub 17 Oct 2015). Ultsch B, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics (Epub 17 Oct 2015).
49.
go back to reference Sisk JE, et al. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med. 2003;138(12):960–8.CrossRefPubMed Sisk JE, et al. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med. 2003;138(12):960–8.CrossRefPubMed
50.
go back to reference Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31–32):4203–14.CrossRefPubMed Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31–32):4203–14.CrossRefPubMed
51.
go back to reference Lexau CA, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. J Am Med Assoc. 2005;294(16):2043–51.CrossRef Lexau CA, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. J Am Med Assoc. 2005;294(16):2043–51.CrossRef
52.
go back to reference Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis. 2000;30(6):931–3.CrossRefPubMed Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis. 2000;30(6):931–3.CrossRefPubMed
53.
go back to reference Prince MJ, et al. The burden of disease in older people and implications for health policy and practice. Lancet. 2015;385(9967):549–62.CrossRefPubMed Prince MJ, et al. The burden of disease in older people and implications for health policy and practice. Lancet. 2015;385(9967):549–62.CrossRefPubMed
54.
go back to reference Lang PO, et al. Immunosenescence: Implications for vaccination programmes in adults. Maturitas. 2011;68(4):322–30.CrossRefPubMed Lang PO, et al. Immunosenescence: Implications for vaccination programmes in adults. Maturitas. 2011;68(4):322–30.CrossRefPubMed
55.
go back to reference Smith KJ, et al. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in US older adults. Am J Prevent Med. 2013;44(4):373–81. Smith KJ, et al. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in US older adults. Am J Prevent Med. 2013;44(4):373–81.
56.
go back to reference Drummond MF, et al. Methods for the economic evaluation of helath care programmes. 3rd ed. Oxford: Oxford University Press; 2005. Drummond MF, et al. Methods for the economic evaluation of helath care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
57.
go back to reference Pradas R, et al. Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model. BMC Infect Dis. 2013;13(1):175.CrossRefPubMedPubMedCentral Pradas R, et al. Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model. BMC Infect Dis. 2013;13(1):175.CrossRefPubMedPubMedCentral
58.
go back to reference Lal H, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.CrossRefPubMed Lal H, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.CrossRefPubMed
59.
go back to reference Lambrecht BN, et al. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol. 2009;21(1):23–9.CrossRefPubMed Lambrecht BN, et al. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol. 2009;21(1):23–9.CrossRefPubMed
60.
go back to reference Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine. 2008;26(26):3197–208.CrossRefPubMed Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine. 2008;26(26):3197–208.CrossRefPubMed
61.
go back to reference Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494–500.CrossRefPubMed Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494–500.CrossRefPubMed
62.
go back to reference Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Recommended adult immunization schedule-United States. MMWR. 2012;61–84. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Recommended adult immunization schedule-United States. MMWR. 2012;61–84.
63.
go back to reference Andrews RM, et al. Influenza and pneumococcal vaccine coverage among a random sample of hospitalised persons aged 65 years or more, Victoria. Commun Dis Intell Q Rep. 2005;29(3):283–8.PubMed Andrews RM, et al. Influenza and pneumococcal vaccine coverage among a random sample of hospitalised persons aged 65 years or more, Victoria. Commun Dis Intell Q Rep. 2005;29(3):283–8.PubMed
64.
go back to reference Blank PR, Schwenkglenks M, Szucs TD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect. 2009;58(6):446–58.CrossRefPubMed Blank PR, Schwenkglenks M, Szucs TD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect. 2009;58(6):446–58.CrossRefPubMed
66.
go back to reference Eilers R, Krabbe PF, de Melker HE. Factors affecting the uptake of vaccination by the elderly in Western society. Prevent Med. 2014;69:224–34.CrossRef Eilers R, Krabbe PF, de Melker HE. Factors affecting the uptake of vaccination by the elderly in Western society. Prevent Med. 2014;69:224–34.CrossRef
67.
go back to reference Ridda I, et al. Factors associated with pneumococcal immunisation among hospitalised elderly persons: a survey of patient’s perception, attitude, and knowledge. Vaccine. 2008;26(2):234–40.CrossRefPubMed Ridda I, et al. Factors associated with pneumococcal immunisation among hospitalised elderly persons: a survey of patient’s perception, attitude, and knowledge. Vaccine. 2008;26(2):234–40.CrossRefPubMed
69.
go back to reference Van Hoek AJ, et al. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine. 2012;30(6):1225–34.CrossRefPubMed Van Hoek AJ, et al. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine. 2012;30(6):1225–34.CrossRefPubMed
70.
go back to reference Van Den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl. 1):i89–i91. Van Den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl. 1):i89–i91.
71.
go back to reference Hawthorne G, Osborne R. Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. Aust N Z J Public Health. 2005;29(2):136–42.CrossRefPubMed Hawthorne G, Osborne R. Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. Aust N Z J Public Health. 2005;29(2):136–42.CrossRefPubMed
74.
75.
go back to reference Rocklöv J, Forsberg B, Meister K. Winter mortality modifies the heat-mortality association the following summer. Eur Respir J. 2009;33(2):245–51.CrossRefPubMed Rocklöv J, Forsberg B, Meister K. Winter mortality modifies the heat-mortality association the following summer. Eur Respir J. 2009;33(2):245–51.CrossRefPubMed
76.
go back to reference Jit M, Mibei W. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: a critical review. Vaccine. 2015;33(32):3788–94.CrossRefPubMed Jit M, Mibei W. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: a critical review. Vaccine. 2015;33(32):3788–94.CrossRefPubMed
77.
78.
go back to reference Vynnycky E, White RG. An introduction to infectious disease modelling. Oxford: Oxford University Press; 2011. Vynnycky E, White RG. An introduction to infectious disease modelling. Oxford: Oxford University Press; 2011.
79.
go back to reference Mossong J, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008;5(3):0381–91.CrossRef Mossong J, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008;5(3):0381–91.CrossRef
80.
go back to reference Pitsiou GG, Kioumis IP. Pneumococcal vaccination in adults: does it really work? Respir Med. 2011;105(12):1776–83.CrossRefPubMed Pitsiou GG, Kioumis IP. Pneumococcal vaccination in adults: does it really work? Respir Med. 2011;105(12):1776–83.CrossRefPubMed
81.
go back to reference Chiu C, Dey A, Wang H. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell. 2010;34(Suppl):S1–167.CrossRef Chiu C, Dey A, Wang H. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell. 2010;34(Suppl):S1–167.CrossRef
82.
go back to reference Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol. 2003;70(Suppl. 1):S31–7.CrossRefPubMed Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol. 2003;70(Suppl. 1):S31–7.CrossRefPubMed
Metadata
Title
Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges
Authors
Sevan Dirmesropian
James G. Wood
C. Raina MacIntyre
Philippe Beutels
Anthony T. Newall
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 8/2016
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-016-0393-0

Other articles of this Issue 8/2016

PharmacoEconomics 8/2016 Go to the issue